Real-World Findings Reinforce Encelto’s Role in MacTel Treatment

Roger A. Goldberg, MD, MBA, shared early postapproval experience with Encelto, including an evolving surgical technique, at Clinical Trials at the Summit.

By
Jim Gallagher, senior managing editor
June 1, 2026
4 min

Retinal Physician

Objective:

To present early postapproval experiences and outcomes associated with Encelto in the treatment of macular telangiectasia type 2 (MacTel).

Approach:

Key Findings:

Pooled data from three randomized, sham-controlled studies demonstrated a 36% reduction in photoreceptor loss over two years.
Treatment resulted in a 68% reduction in the loss of monocular reading speed and a 35% reduction in retinal sensitivity loss compared to controls.
Real-world safety findings were consistent with clinical trials, with approximately 20% of patients experiencing mild delayed dark adaptation and miosis.

Interpretation:

Younger patients, those with smaller areas of ellipsoid zone loss, and those without foveal involvement are identified as the strongest responders to Encelto.